Celyad Oncology SA (FRA:1C0)

Celyad Oncology Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jan 9, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	8	29	16	11	79	92
Market Cap Growth	-71.24%	82.56%	41.33%	-85.61%	-13.96%	-31.75%
Enterprise Value	9	24	12	-1	76	69
Last Close Price	0.15	0.66	0.34	0.47	3.37	6.42
PS Ratio	45.60	158.59	158.40	-	-	18459.66
PB Ratio	-2.74	57.72	2.56	2.65	1.82	2.98
P/TBV Ratio	-	60.45	2.58	2.96	10.00	-
EV/Sales Ratio	45.82	130.42	114.87	-	-	13862.06
Debt / Equity Ratio	-0.27	1.77	0.17	0.06	0.06	0.12
Asset Turnover	0.02	0.01	0.01	-	-	0
Quick Ratio	0.42	1.79	3.34	1.31	2.34	1.53
Current Ratio	0.66	2.29	3.79	1.42	2.48	1.67
Return on Equity (ROE)	-7871.95%	-170.92%	-159.08%	-170.72%	-71.05%	-44.91%
Return on Assets (ROA)	-43.41%	-27.99%	-33.14%	-31.92%	-23.32%	-21.04%
Return on Capital (ROIC)	-405.75%	-83.59%	-99.97%	-62.57%	-42.08%	-38.76%
Return on Capital Employed (ROCE)	-325.40%	-82.90%	-71.50%	-273.90%	-41.20%	-48.40%
Earnings Yield	-76.10%	-19.74%	-52.29%	-358.06%	-33.38%	-18.64%
FCF Yield	-	-19.26%	-99.65%	-246.08%	-33.97%	-30.14%
Buyback Yield / Dilution	-17.90%	-61.06%	-13.84%	-44.80%	-11.92%	-11.33%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.